Report : US Helicobacter Pylori Non-Invasive Testing Market Forecast to 2028 - COVID-19 Impact and Country Analysis By Test Type (Urea Breath, Test Method, and Serology), Test Method (Laboratories Based and Point of Care), and End User (Hospitals, Reference Laboratories, and Others)
According to our new research study on “US H. pylori Non-Invasive Testing Market Forecast to 2028 – COVID-19 Impact and Country Analysis – by Test Type, Test Method, and End User,” the market is expected to grow from US$ 223.76 million in 2022 to US$ 302.79 million by 2028; it is estimated to record a CAGR 5.3% during 2023–2028. Factors like the increasing prevalence of H. pylori bacterial infection, rising market development activities in H. pylori non-invasive testing are boosting the market over the years are driving the US H. pylori non-invasive testing market growth.
Helicobacter Pylori (H. pylori) is a very motile, spiral, or curved rod-shaped gram-negative bacteria comprising multiple flagella that live in the gastric mucous-coated lining and the gastric pits of the epithelial tissue of the stomach and/or duodenum. Currently, non-invasive tests are the first methods for diagnosing H. pylori infection. For example, serological tests, stool antigen research, and urea breath test are widely used. The urea breath test holds the major US H. pylori non-invasive testing market share and expected to anticipate the highest CAGR.
A UBT is one of the essential noninvasive methods for detecting H. pylori infection. The test involves detecting H. pylori based on its ability to produce urease enzyme, which results in the hydrolysis of orally administered urea into carbon dioxide and ammonia. These gases diffuse into the blood, and the lungs then excrete them. UBTs are reliable, low-burden tests validated in adults and children.
According to Cancer Research UK, chronic bacterial infection causes long-lasting stomach inflammation, also known as severe chronic atrophic gastritis or SCAG; prolonged stomach ulcers can even lead to cancer. According to the World Health Organization (WHO), cancer is a significant cause of death across the world; approximately 1.9 million new cancer cases were recorded in the world in 2021. Colorectal cancer is a common type, with 146,589 new cases recorded in 2022. This type of cancer is more prevalent in middle-aged and geriatric populations. It rarely occurs among people aged less than 40 with genetic predisposition or predisposing conditions. The early detection of H. pylori via appropriate tests is necessary to prevent colorectal cancer. Early diagnosis is pivotal to reducing cancer-related mortality rates. Thus, the rising cases of bacterial infections are necessitating urea breath tests and contributing to the overall US H. pylori non-invasive testing market size.
In February 2020, Gulf Coast Scientific received approval from the US Food and Drug Administration (FDA) for the Pylo Plus UBT System, a 13C UBT for the detection of H. pylori infection. In addition, key players in the US H. pylori noninvasive testing market form alliances to introduce new products and expand their presence. For instance, in 2021, Meridian Bio signed an agreement to acquire BreahTrek from Otsuka Pharmaceutical for US$ 20 million. Such collaborations led to the new product launches in the UBT segment and contribute the overall growth of US H. pylori non-invasive testing market during the forecast period.
Bioneer Corp, Meridian Bioscience Inc, Abbott Laboratories, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Coris Bioconcept SPRL, DiaSorin SpA, Sekisui Diagnostics LLC, CerTest Biotec SL, and QuidelOrtho Corporation, and among others are among the key companies operating in the US H. pylori non-invasive testing market. Leading players adopt strategies such as the launch of new products, expansion and diversification of their market presence, and expansion of new customer base for tapping prevailing business opportunities.
The report segments US H. pylori non-invasive testing market as follows:
The US H. pylori non-invasive testing market is segmented on the basis of test type, test method, and end user. Based on the type, the market is segmented into urea breath, stool antigen, and serology. Based on test method, the US H. pylori non-invasive testing market is bifurcated into laboratories based and point of care. By end user, the US H. pylori non-invasive testing market is segmented into hospitals, reference laboratories, and others.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com